MiR-1248: a new prognostic biomarker able to identify supratentorial hemispheric pediatric low-grade gliomas patients associated with progression

authors

• Catanzaro Giuseppina
• Besharat Zein Mersini
• Carai Andrea
• Jäger Natalie
• Splendiani Elena
• Colin Carole
• Po Agnese
• Chiacchiarini Martina
• Citarella Anna
• Gianno Francesca
• Cacchione Antonella
• Miele Evelina
• Diomedi Camassei Francesca
• Gessi Marco
• Massimi Luca
• Locatelli Franco
• Jones David
• Figarella‑branger Dominique
• Pfister Stefan
• Mastronuzzi Angela
• Giangaspero Felice
• Ferretti Elisabetta

keywords

• Pediatric low-grade gliomas
• MiR-1248
• Prognostic biomarker
• Tumour progression
• Risk stratification
• Personalized medicine

document type

abstract

Background Pediatric low-grade gliomas (pLGGs), particularly incompletely resected supratentorial tumours, can undergo progression after surgery. However to date, there are no predictive biomarkers for progression. Here, we aimed to identify pLGG-specific microRNA signatures and evaluate their value as a prognostic tool. Methods We identified and validated supratentorial incompletey resected pLGG-specific microRNAs in independent cohorts from four European Pediatric Neuro-Oncology Centres. Results These microRNAs demonstrated high accuracy in differentiating patients with or without progression. Specifically, incompletely resected supratentorial pLGGs with disease progression showed significantly higher miR-1248 combined with lower miR-376a-3p and miR-888-5p levels than tumours without progression. A significant ( p < 0.001) prognostic performance for miR-1248 was reported with an area under the curve (AUC) of 1.00. We also highlighted a critical oncogenic role for miR-1248 in gliomas tumours. Indeed, high miR-1248 levels maintain low its validated target genes (CDKN1A (p21)/FRK/SPOP/VHL/MTAP) and consequently sustain the activation of oncogenic pathways. Conclusions Altogether, we provide a novel molecular biomarker able to successfully identify pLGG patients associated with disease progression that could support the clinicians in the decision-making strategy, advancing personalized medicine.

more information